BioSpace News Archive

Drug Development

Versanis Announces Initiation of the BELIEVE Global Phase 2b Study of Bimagrumab as a Novel Treatment for Obesity

Versanis Bio today announced that the BELIEVE Phase 2b study to assess the safety and efficacy of bimagrumab alone and in combination with semaglutide for the treatment of obesity has begun enrolling at sites in the U.S., Australia, and New Zealand.

January 12, 2023
·
4 min read
BioMidwest

Panbela Announces 1-for-40 Reverse Stock Split effective January 13, 2023

Panbela Therapeutics, Inc., a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that it will implement the previously announced and stockholder approved 1-for-40 reverse split of its common stock.

January 12, 2023
·
5 min read
Genetown

Aitia and G3 Therapeutics Publish Results Identifying New Causal Biomarkers of Atherosclerotic Coronary Artery Disease (ASCAD), the Leading Cause of Morbidity and Mortality Worldwide

G3 Therapeutics and Aitia, the leader in the application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced results of research that identified new causes of ASCAD.

January 12, 2023
·
5 min read
Biotech Bay

Terns Pharmaceuticals to Present at B. Riley Securities’ 3rd Annual Oncology Conference

Terns Pharmaceuticals, Inc. today announced that management will participate in a fireside chat at the B. Riley Securities 3rd Annual Oncology Conference on Wednesday, January 18, 2023 at 2:30 p.m.

January 12, 2023
·
1 min read